source
- Merck’s eye-drug matches Lucentis in vision improvement but raises safety concernsMerck reported results from its Phase 2b/3 BRUNELLO trial of remigromig, a Wnt-pathway agonist for diabetic macular edema. The drug achieved non-inferior improvement in best-corrected visual acuit…
- FDA nominee Heidi Overton pledges faster, more efficient regulation to keep pace with ChinaDuring a Senate hearing, Heidi Overton was confirmed as the nominee to lead the U.S. Food and Drug Administration. She outlined her priorities for the agency. Overton said the FDA must move faster…